全文获取类型
收费全文 | 2137篇 |
免费 | 133篇 |
国内免费 | 57篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 97篇 |
妇产科学 | 43篇 |
基础医学 | 255篇 |
口腔科学 | 51篇 |
临床医学 | 219篇 |
内科学 | 532篇 |
皮肤病学 | 86篇 |
神经病学 | 142篇 |
特种医学 | 321篇 |
外科学 | 155篇 |
综合类 | 31篇 |
一般理论 | 1篇 |
预防医学 | 158篇 |
眼科学 | 16篇 |
药学 | 108篇 |
中国医学 | 5篇 |
肿瘤学 | 99篇 |
出版年
2023年 | 18篇 |
2022年 | 21篇 |
2021年 | 46篇 |
2020年 | 23篇 |
2019年 | 30篇 |
2018年 | 62篇 |
2017年 | 25篇 |
2016年 | 26篇 |
2015年 | 35篇 |
2014年 | 45篇 |
2013年 | 84篇 |
2012年 | 85篇 |
2011年 | 77篇 |
2010年 | 73篇 |
2009年 | 77篇 |
2008年 | 84篇 |
2007年 | 115篇 |
2006年 | 84篇 |
2005年 | 68篇 |
2004年 | 55篇 |
2003年 | 62篇 |
2002年 | 53篇 |
2001年 | 55篇 |
2000年 | 45篇 |
1999年 | 45篇 |
1998年 | 79篇 |
1997年 | 89篇 |
1996年 | 106篇 |
1995年 | 68篇 |
1994年 | 65篇 |
1993年 | 55篇 |
1992年 | 28篇 |
1991年 | 29篇 |
1990年 | 31篇 |
1989年 | 50篇 |
1988年 | 44篇 |
1987年 | 41篇 |
1986年 | 55篇 |
1985年 | 52篇 |
1984年 | 16篇 |
1983年 | 17篇 |
1982年 | 13篇 |
1981年 | 9篇 |
1980年 | 12篇 |
1979年 | 13篇 |
1978年 | 13篇 |
1977年 | 9篇 |
1976年 | 13篇 |
1975年 | 13篇 |
1969年 | 3篇 |
排序方式: 共有2327条查询结果,搜索用时 15 毫秒
91.
Fiona?J?CharlsonEmail author Andrew?E?Moran Greg?Freedman Rosana?E?Norman Nicolas?JC?Stapelberg Amanda?J?Baxter Theo?Vos Harvey?A?Whiteford 《BMC medicine》2013,11(1):250
Background
Cardiovascular disease and mental health both hold enormous public health importance, both ranking highly in results of the recent Global Burden of Disease Study 2010 (GBD 2010). For the first time, the GBD 2010 has systematically and quantitatively assessed major depression as an independent risk factor for the development of ischemic heart disease (IHD) using comparative risk assessment methodology.Methods
A pooled relative risk (RR) was calculated from studies identified through a systematic review with strict inclusion criteria designed to provide evidence of independent risk factor status. Accepted case definitions of depression include diagnosis by a clinician or by non-clinician raters adhering to Diagnostic and Statistical Manual of Mental Disorders (DSM) or International Classification of Diseases (ICD) classifications. We therefore refer to the exposure in this paper as major depression as opposed to the DSM-IV category of major depressive disorder (MDD). The population attributable fraction (PAF) was calculated using the pooled RR estimate. Attributable burden was calculated by multiplying the PAF by the underlying burden of IHD estimated as part of GBD 2010.Results
The pooled relative risk of developing IHD in those with major depression was 1.56 (95% CI 1.30 to 1.87). Globally there were almost 4 million estimated IHD disability-adjusted life years (DALYs), which can be attributed to major depression in 2010; 3.5 million years of life lost and 250,000 years of life lived with a disability. These findings highlight a previously underestimated mortality component of the burden of major depression. As a proportion of overall IHD burden, 2.95% (95% CI 1.48 to 4.46%) of IHD DALYs were estimated to be attributable to MDD in 2010. Eastern Europe and North Africa/Middle East demonstrate the highest proportion with Asia Pacific, high income representing the lowest.Conclusions
The present work comprises the most robust systematic review of its kind to date. The key finding that major depression may be responsible for approximately 3% of global IHD DALYs warrants assessment for depression in patients at high risk of developing IHD or at risk of a repeat IHD event.92.
BO Motayo PA Akinduti FA Adeyakinu PO Okerentugba JC Nwanze CC Onoh HC Innocent-Adiele IO Okonko 《African health sciences》2013,13(4):1091-1097
Background
The increased reports of ESBL dissemination from various centres in south western, Nigeria and the recent emergence of carbapenem resistant bacteria prompted the conception of this study.Objectives
To demonstrate the relationship between high molecular weight plasmids and the expression of antibiotic multi-resistance including ESBL and carbapenemase.Methods
We investigated 97 isolates of selected organisms consisting of 67 E. coli and 30 Klebseilla spp for the presence of plasmids expressing ESBL including carbapenem-hydrolysing enzymes. Beta-lactamase was determined using acidometric method, while ESBL and carbapenemase activity was determined using the double-disk diffusion test as well as the Modified Hodge test (MHT). Plasmid profiles of ESBL and carbapenemase positive isolates were determined according to standard protocols.Results
An ESBL prevalence rate of 21.6% and carbapenem- resistance rate of 9.3% was recorded. Antibiotic susceptibility profile of ESBL isolates showed 100.0% resistance against Amoxicillin, Cotrimoxazole and Erythromycin. Moderate susceptibility was recorded against the Quinolone class of antibiotics; Meropenem remained the most active antibiotic against ESBL isolates with 62.5% against E. coli and 60% against K. pneumoniae. The plasmid profiles of our study isolates ranged from 11.8kbp to 35.5kbp.Conclusion
Due to the relationship between high molecular weight plasmids and multi-drug resistance, we hereby recommend regular molecular surveillance of this form in our study setting. 相似文献93.
Fuster O Barragán E Bolufer P Such E Valencia A Ibáñez M Dolz S de Juan I Jiménez A Gómez MT Buño I Martínez J Cervera J Montesinos P Moscardó F Sanz MÁ 《Annals of hematology》2012,91(1):1-7
During last years, molecular markers have been increased as prognostic factors routinely screened in acute myeloid leukemia (AML). Recently, an increasing interest has been reported in introducing to clinical practice screening for mutations in the CCAAT/enhancer-binding protein ?? (CEBPA) gene in AML, as it seems to be a good prognostic factor. However, there is no reliable established method for assessing CEBPA mutations during the diagnostic work-up of AMLs. We describe here a straightforward and reliable fragment analysis method based in PCR capillary electrophoresis (PCR-CE) for screening of CEBPA mutations; moreover, we present the results obtained in 151 intermediate-risk karyotype AML patients (aged 16?C80?years). The method gave a specificity of 100% and sensitivity of 93% with a lower detection limit of 1?C5% for CEBPA mutations. The series found 19 mutations and four polymorphisms in 12 patients, seven of whom (58%) presented two mutations. The overall frequency of CEBPA mutations in AML was 8% (n?=?12). CEBPA mutations showed no coincidence with FLT3-ITD or NPM1 mutations. CEBPA mutation predicted better disease-free survival in the group of patients without FLT3-ITD, NPM, or both genes mutated (HR 3.6, IC 95%; 1.0?C13.2, p?=?0.05) and better overall survival in patients younger than 65 of this group without molecular markers (HR 4.0, IC 95%; 1.0?C17.4, p?=?0.05). In conclusion, the fragment analysis method based in PCR-CE is a rapid, specific, and sensitive method for CEBPA mutation screening and our results confirm that CEBPA mutations can identify a subgroup of patients with favorable prognosis in AML with intermediate-risk karyotype. 相似文献
94.
95.
96.
Bone morphogenetic protein-2/4 signalling pathway components are expressed in the human thymus and inhibit early T-cell development 下载免费PDF全文
Cejalvo T Sacedón R Hernández-López C Diez B Gutierrez-Frías C Valencia J Zapata AG Varas A Vicente A 《Immunology》2007,121(1):94-104
T-cell differentiation is driven by a complex network of signals mainly derived from the thymic epithelium. In this study we demonstrate in the human thymus that cortical epithelial cells produce bone morphogenetic protein 2 (BMP2) and BMP4 and that both thymocytes and thymic epithelium express all the molecular machinery required for a response to these proteins. BMP receptors, BMPRIA and BMPRII, are mainly expressed by cortical thymocytes while BMPRIB is expressed in the majority of the human thymocytes. Some thymic epithelial cells from cortical and medullary areas express BMP receptors, being also cell targets for in vivo BMP2/4 signalling. The treatment with BMP4 of chimeric human-mouse fetal thymic organ cultures seeded with CD34+ human thymic progenitors results in reduced cell recovery and inhibition of the differentiation of human thymocytes from CD4- CD8- to CD4+ CD8+ cell stages. These results support a role for BMP2/4 signalling in human T-cell differentiation. 相似文献
97.
98.
99.
JC Jiménez-Mendoza FE Rivera-López MF González-Lara RD Valdez-Echeverría GE Castro-Narro A Tore LF Uscanga-Domínguez C Moctezuma-Velázquez 《Annals of hepatology》2022,27(3):100684
Introduction and ObjectivesThe emergence of SARS-CoV-2, which causes the coronavirus disease (COVID-19) has caused a great impact on healthcare systems worldwide, including hepatitis B and C viruses screening and elimination programs. The high number of COVID-19 hospitalizations represent a great opportunity to screen patients for hepatitis B virus (HBV) and hepatitis C virus (HCV), which was the aim of this study.Material and MethodsCross-sectional, retrospective study performed between April 2020 and 20201 at a referral center in Mexico dedicated to the care of adults with severe/critical COVID-19. We retrieved clinical, demographic, and laboratory results from each patient´s medical records, including antibodies against HCV (anti-HCV), HBV surface antigen (HBsAg), antibodies against the HBV core antigen (anti-HBcAg), and antibodies against HBsAg (anti-HBsAg).ResultsOut of 3620 patients that were admitted to the hospital, 24 (0.66%), 4 (0.11%), and 72 (1.99%) tested positive for anti-HCV, HBsAg, and anti-HBcAg, respectively. Of all seronegative patients, 954 (27%) had undetectable anti-HBsAg and 401 (12%) had anti-HBsAg at protective levels. Blood transfusion was the most relevant risk factor. Only 9.7% of the anti-HBc positive, 25% of the HBsAg positive, and 52% of the anti-HCV positive were aware of their serological status.ConclusionsIn this study we found a prevalence of anti-HCV of 0.66%, HBsAg in 0.11%, and isolated anti-HBcAg in 1.99%. We also found that HBV vaccination coverage has been suboptimal and needs to be reinforced. This study gave us a trustworthy insight of the actual seroprevalence in Mexico, which can help provide feedback to the Hepatitis National Elimination Plan. 相似文献
100.
Kaneshka Masdjedi MD Laurens JC van Zandvoort BSc Matthew M Balbi MD Rutger-Jan Nuis MD PhD Jeroen Wilschut MD Roberto Diletti MD PhD Peter P.T. de Jaegere MD PhD Felix Zijlstra MD PhD Nicolas M Van Mieghem MD PhD Joost Daemen MD PhD 《Catheterization and cardiovascular interventions》2021,98(4):671-677